LanZhou Foci Pharmaceutical Co.,Ltd. (SHE:002644)
China
· Delayed Price · Currency is CNY 9.15
+0.24 (2.69%)
At close: Mar 10, 2026
SHE:002644 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 892.97 | 977.45 | 1,158 | 1,041 | 809.39 | 659.96 | Upgrade
|
| Other Revenue | 2.78 | 2.78 | 5.45 | 1.58 | 8.25 | 8.09 | Upgrade
|
| Revenue | 895.75 | 980.23 | 1,163 | 1,042 | 817.64 | 668.05 | Upgrade
|
| Revenue Growth (YoY) | -9.41% | -15.73% | 11.58% | 27.49% | 22.39% | 6.24% | Upgrade
|
| Cost of Revenue | 618.46 | 681.46 | 804.17 | 738.23 | 596.57 | 503.63 | Upgrade
|
| Gross Profit | 277.29 | 298.76 | 358.96 | 304.16 | 221.07 | 164.42 | Upgrade
|
| Selling, General & Admin | 161.02 | 184.21 | 236.74 | 181.6 | 131.27 | 119.61 | Upgrade
|
| Research & Development | 25.59 | 29.28 | 30.93 | 23.56 | 19.36 | 15.38 | Upgrade
|
| Other Operating Expenses | 10.95 | 11.37 | 13.32 | 14.53 | 14.82 | 12.04 | Upgrade
|
| Operating Expenses | 235.06 | 254.63 | 296.07 | 238.06 | 175.42 | 151.14 | Upgrade
|
| Operating Income | 42.23 | 44.13 | 62.9 | 66.1 | 45.65 | 13.28 | Upgrade
|
| Interest Expense | -1.54 | -0.83 | -1.24 | -1.35 | -0.95 | -1.28 | Upgrade
|
| Interest & Investment Income | 4.59 | 5.74 | 5.37 | 7.51 | 10.2 | 12.82 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.3 | 0.3 | 1.08 | 2.15 | -0.33 | -0.37 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.5 | -3.95 | -1.43 | -17.88 | -1.22 | 0.89 | Upgrade
|
| EBT Excluding Unusual Items | 41.07 | 45.38 | 66.67 | 56.53 | 53.36 | 25.34 | Upgrade
|
| Gain (Loss) on Sale of Investments | -6.33 | -7.23 | -4.49 | -1.3 | -0.85 | -4.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.03 | 0.04 | - | 0 | 27.18 | 70.59 | Upgrade
|
| Asset Writedown | 0.02 | - | -0 | -0.2 | -0.37 | 0.15 | Upgrade
|
| Legal Settlements | - | - | - | - | 0.01 | - | Upgrade
|
| Other Unusual Items | 30.94 | 30.94 | 19.46 | 75.68 | 31.48 | 38.48 | Upgrade
|
| Pretax Income | 65.74 | 69.14 | 81.64 | 130.72 | 110.81 | 130.52 | Upgrade
|
| Income Tax Expense | 7.38 | 7.47 | 13.52 | 21.37 | 17.3 | 22.81 | Upgrade
|
| Earnings From Continuing Operations | 58.36 | 61.67 | 68.12 | 109.35 | 93.52 | 107.71 | Upgrade
|
| Minority Interest in Earnings | 0.72 | -1.6 | -0.93 | -0.69 | -0.26 | 0.31 | Upgrade
|
| Net Income | 59.08 | 60.07 | 67.19 | 108.65 | 93.26 | 108.02 | Upgrade
|
| Net Income to Common | 59.08 | 60.07 | 67.19 | 108.65 | 93.26 | 108.02 | Upgrade
|
| Net Income Growth | 27.94% | -10.60% | -38.16% | 16.51% | -13.66% | 44.31% | Upgrade
|
| Shares Outstanding (Basic) | 511 | 511 | 511 | 511 | 511 | 511 | Upgrade
|
| Shares Outstanding (Diluted) | 511 | 511 | 511 | 511 | 511 | 511 | Upgrade
|
| Shares Change (YoY) | -0.03% | 0.05% | -0.01% | -0.03% | 0.00% | 0.03% | Upgrade
|
| EPS (Basic) | 0.12 | 0.12 | 0.13 | 0.21 | 0.18 | 0.21 | Upgrade
|
| EPS (Diluted) | 0.12 | 0.12 | 0.13 | 0.21 | 0.18 | 0.21 | Upgrade
|
| EPS Growth | 27.98% | -10.64% | -38.16% | 16.54% | -13.66% | 44.27% | Upgrade
|
| Free Cash Flow | 132.37 | 25.7 | 43.24 | 45.08 | -20.95 | -59.69 | Upgrade
|
| Free Cash Flow Per Share | 0.26 | 0.05 | 0.09 | 0.09 | -0.04 | -0.12 | Upgrade
|
| Dividend Per Share | 0.012 | 0.012 | 0.030 | 0.050 | 0.010 | 0.120 | Upgrade
|
| Dividend Growth | -60.00% | -60.00% | -40.00% | 400.00% | -91.67% | 100.00% | Upgrade
|
| Gross Margin | 30.96% | 30.48% | 30.86% | 29.18% | 27.04% | 24.61% | Upgrade
|
| Operating Margin | 4.71% | 4.50% | 5.41% | 6.34% | 5.58% | 1.99% | Upgrade
|
| Profit Margin | 6.60% | 6.13% | 5.78% | 10.42% | 11.41% | 16.17% | Upgrade
|
| Free Cash Flow Margin | 14.78% | 2.62% | 3.72% | 4.32% | -2.56% | -8.94% | Upgrade
|
| EBITDA | 90.54 | 93.76 | 114.29 | 114.96 | 93.58 | 58.42 | Upgrade
|
| EBITDA Margin | 10.11% | 9.56% | 9.83% | 11.03% | 11.45% | 8.74% | Upgrade
|
| D&A For EBITDA | 48.3 | 49.63 | 51.39 | 48.86 | 47.92 | 45.13 | Upgrade
|
| EBIT | 42.23 | 44.13 | 62.9 | 66.1 | 45.65 | 13.28 | Upgrade
|
| EBIT Margin | 4.71% | 4.50% | 5.41% | 6.34% | 5.58% | 1.99% | Upgrade
|
| Effective Tax Rate | 11.23% | 10.81% | 16.56% | 16.35% | 15.61% | 17.48% | Upgrade
|
| Revenue as Reported | 895.75 | 980.23 | 1,163 | 1,042 | 817.64 | 668.05 | Upgrade
|
| Advertising Expenses | - | 7.68 | 37.86 | 22.29 | 15.73 | 22.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.